Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis

Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis: a Mechanistic FDG-PET Study

Transcranial Direct Current Stimulation (tDCS) is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in patients with multiple sclerosis (PwMS.) In spite of the encouraging results of tDCS in PwMS, detailed mechanisms accounting for its analgesic effect have not yet been elucidated.

This will be the first study to determine the effects of tDCS on whole and regional brain activity in PwMS with neuropathic pain to identify potential mechanisms of the analgesic effects of tDCS. These findings will provide targets for future studies investigating different stimulation areas, possible short- and long-term side effects, and specific target areas for other precise stimulation techniques such as transcranial magnetic stimulation.

Study Overview

• Status: Terminated
• Conditions: Multiple Sclerosis; Neuropathic Pain
• Intervention / Treatment: Device: SHAM tDCS using tDCS device; Device: Active tDCS using tDCS device

Detailed Description

The investigators aim is to identify changes in brain activation following transcranial direct current stimulation (tDCS), and determine whether these changes are associated with reduced ratings of pain. The investigators hypothesize that the analgesic effects of tDCS are associated with altered glucose metabolism of key regions of the top-down pain modulatory system, such as the dorsolateral prefrontal cortex (DLPFC) and medulla.

This study will follow an interventional protocol with two groups. Upon enrollment into the study, all participants will undergo testing for the outcome measures described above. Each participant will then be randomly assigned into the SHAM or tDCS group for the study intervention. This study will be completed over the course of 6 consecutive days and 1 follow-up phone call 1 week after the final testing for each participant (total of 13 days).

Two age and sex matched groups, each n =8, will receive either tDCS or SHAM stimulation.

All of the following measures will be performed before and after the tDCS or SHAM intervention.

Fluorodeoxyglucose ([18F] FDG) - Whole and regional brain FDG uptake will be measured to determine the mechanistic effect of tDCS on brain activity.

Visual Analog Scale (VAS) - The VAS is a self-evaluation scale where the participant is asked to mark a segment that ranges from 0-100 as visually described in millimeter units where 0 mm indicates no pain and 100 mm indicates the worst possible pain. This scale has been widely used in studies that evaluated pain as an outcome measure: both validity and reproducibility have been demonstrated.

VAS for Anxiety - This is a self-evaluation scale that ranges from 0 to 100 mm: 0 mm indicates no anxiety and 100 mm indicates the worst possible anxiety.

Prior to beginning the 2nd-5th tDCS sessions, the effectiveness of tDCS will be assessed using the following procedures:

Visual Analog Scale (VAS) - Each participant will be asked how effective the previous day's tDCS session was at reducing their pain by marking a segment on the range of 0-100 as visually described in millimeter units where 0 mm indicates no reduction in pain and 100 mm indicates complete alleviation of pain.

Duration of Relief - If the participant indicates any reduction in pain following the previous day's tDCS session, the participant will be asked to estimate how long the participant's pain was reduced following the session.

One week following the post-intervention testing, participants will be contacted via telephone and asked the following questions:

1. Was tDCS effective at reducing the participant's pain?
2. If so, how long did the participant notice a reduction in pain following the participant's final tDCS session?
3. Have the participants reduced their use of pain relieving medications since the last tDCS session?

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Denver

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with Multiple Sclerosis (PwMS)
• Age range 18-65
• Expanded disability status scale comprised between 1.5 and 6.5 with relapsing remitting MS (RRMS) in remitting phase
• Presenting with chronic, drug-resistant, neuropathic pain
• Patients must score at or above a 0 on the Neuropathic Pain Questionnaire (NPQ).
• Patients must score at least a 40 mm on the visual analog scale (VAS) for pain perception at baseline
• All analgesic medications discontinued at least 24 hours before entering the study

Exclusion Criteria:

• Any change in:

  • disease-modifying medications, or
  • a relapse of disease symptoms within the last 60 days
• History of seizures
• History of traumatic brain injury
• History of claustrophobia

• Presence of:

  • pacemakers,
  • aneurysm clips,
  • artificial heart valves,
  • metallic prostheses, or
  • pregnancy.
• Recent hospitalization (within the last 3 months)
• Enforced bed rest/sedentary state
• Resting plasma glucose greater than 200 mg/dl
• Presence of other neurological disorders.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Sham Comparator: SHAM tDCS; SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.	Device: SHAM tDCS using tDCS device; SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
Active Comparator: Active tDCS with a tDCS device; Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.	Device: Active tDCS using tDCS device; Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cerebral Glucose Uptake in Patients With Multiple Sclerosis With Neuropathic Pain	Whole and regional brain glucose uptake via positron emission tomography with a glucose analogue tracer will be measured to determine the mechanistic effect of transcranial direct current stimulation on brain activity in subjects. Glucose uptake will be determined in patients with multiple sclerosis who received brain stimulation and patients with multiple sclerosis who received SHAM. The outcome variable is the mean Standardized Uptake Value.	1 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Neuropathic Pain as Recorded on a Visual Analog Scale (VAS).	VAS Scale 0-100 The higher the worse.	1 week
Change in Neuropathic Symptom Inventory	The neuropathic symptom inventory is a 12-item questionnaire. This is a valid and reliable measure of neuropathic pain in adults. The Neuropathic Pain Symptoms Inventory (NPSI) contains 12 items in 5 subscales. The subscales include superficial and deep spontaneous pain, paroxysmal pain, evoked pain, and dysesthesia/paresthesia. Among the 12 items, 10 are scored using a numerical rating scale (NRS), ranging from 0 to 10, assessing the severity of experienced neuropathic pain within the previous 24 hours. Higher scores of NPSI indicate more severe peripheral neuropathy.10 is the highest score and indicates severe peripheral neuropathy. Minimum score is 0 and the maximum score is 120.	1 week

Collaborators and Investigators

• Sponsor: Thorsten Rudroff
• Investigators: Principal Investigator: Thorsten Rudroff, Ph.D., University of Colorado, Denver

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2018
• Primary Completion (Actual): June 16, 2018
• Study Completion (Actual): July 1, 2018

Study Registration Dates

• First Submitted: April 14, 2017
• First Submitted That Met QC Criteria: July 13, 2017
• First Posted (Actual): July 17, 2017

Study Record Updates

• Last Update Posted (Actual): November 29, 2022
• Last Update Submitted That Met QC Criteria: November 7, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: tDCS; transcranial direct current stimulation; multiple sclerosis; neuropathic pain; [18F] FDG-PET CT
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Pain; Neurologic Manifestations; Neuromuscular Diseases; Peripheral Nervous System Diseases; Multiple Sclerosis; Sclerosis; Neuralgia
• Other Study ID Numbers: 17-0690

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No